Metropolitan Health Networks
The 10-second takeaway
For the quarter ended June 30 (Q2), Metropolitan Health Networks missed slightly on revenues and missed estimates on earnings per share.
Compared to the prior-year quarter, revenue improved significantly and GAAP earnings per share dropped significantly.
Margins contracted across the board.
Metropolitan Health Networks booked revenue of $193.4 million. The three analysts polled by S&P Capital IQ looked for revenue of $196.4 million on the same basis. GAAP reported sales were 99% higher than the prior-year quarter's $97.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.12. The two earnings estimates compiled by S&P Capital IQ anticipated $0.17 per share. GAAP EPS of $0.07 for Q2 were 50% lower than the prior-year quarter's $0.14 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 14.7%, 230 basis points worse than the prior-year quarter. Operating margin was 6.4%, 430 basis points worse than the prior-year quarter. Net margin was 1.5%, 460 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $198.4 million. On the bottom line, the average EPS estimate is $0.15.
Next year's average estimate for revenue is $790.8 million. The average EPS estimate is $0.57.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 221 members out of 233 rating the stock outperform, and 12 members rating it underperform. Among 28 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 26 give Metropolitan Health Networks a green thumbs-up, and two give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Metropolitan Health Networks is buy, with an average price target of $10.80.
- Add Metropolitan Health Networks to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.